Prime Medicine Wins Arbitration Against Beam Therapeutics Over AATD Gene-Editing Candidate

Prime Medicine announced a positive, binding resolution of its arbitration with Beam Therapeutics concerning their 2019 collaboration and license agreement. The tribunal ruled Prime Medicine owes no monetary damages and declared that PM647 — a prime-editing candidate for alpha-1 antitrypsin deficiency (AATD) that corrects the E342K (Pi*Z) mutation in SERPINA1 using Prime's universal liver LNP — falls within Prime Medicine's contractual 'Field,' confirming its right to develop and commercialize the program. Prime Medicine plans to submit an IND/CTA filing for PM647 in Q3 2026, with initial clinical data expected in 2027, potentially putting it in direct competition with Beam's own AATD base-editing program (BEAM-302).